Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipragliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipragliflozin SCHEMBL27177473 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL17034641 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL903239 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL23731432 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL29433938 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL24037936 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL29358545 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL337645 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL11971945 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A | |
| Ipragliflozin SCHEMBL9908293 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1SLC6A3CHRM1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294259-B2 | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2019-05-21 | — | — | US | disclosed |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH (CN) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294259-B2 | Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof | GCG, SLC5A1, DPP7 | SLC5A2 6/4885SLC5A1 2/4885SLC6A3 626/4885 |
| US-20170057989-A1 | PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USE THEREOF | GCG, SLC5A1, DPP7 | SLC5A2 6/4885SLC5A1 2/4885SLC6A3 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.